Moderna (MRNA) Stock Given $214 Price Target From Piper Sandler

By Amit Chowdhry ● May 21, 2022
  • The shares of Moderna Inc (NASDAQ: MRNA) have received a $214 price target from Piper Sandler. These are the details.

The shares of Moderna Inc (NASDAQ: MRNA) have received a $214 price target from Piper Sandler. And Piper Sandler analyst Edward Tenthoff maintains an “Overweight” rating on the shares.

Tenthoff adjusted the rating based on pipeline adjustments reflecting current market conditions. And Tenthoff adjusted the model to value Spikevax at $41.3 billion on decreased expected 2022 peak revenues of $20.65 billion compared to a previous estimate for Spikevax value at $94.7 billion.

Disclaimer: This content is intended for informational purposes. Before making any investment, you should do your own analysis.